"Endometrial Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
Descriptor ID |
D016889
|
MeSH Number(s) |
C04.588.945.418.948.585 C13.351.500.852.762.200 C13.351.937.418.875.200
|
Concept/Terms |
Endometrial Neoplasms- Endometrial Neoplasms
- Endometrial Neoplasm
- Neoplasm, Endometrial
- Neoplasms, Endometrial
Endometrial Carcinoma- Endometrial Carcinoma
- Carcinoma, Endometrial
- Carcinomas, Endometrial
- Endometrial Carcinomas
- Endometrial Cancer
- Cancer, Endometrial
- Cancers, Endometrial
- Endometrial Cancers
- Endometrium Cancer
- Cancer, Endometrium
- Cancers, Endometrium
- Cancer of the Endometrium
- Carcinoma of Endometrium
- Endometrium Carcinoma
- Endometrium Carcinomas
- Cancer of Endometrium
- Endometrium Cancers
|
Below are MeSH descriptors whose meaning is more general than "Endometrial Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Endometrial Neoplasms".
This graph shows the total number of publications written about "Endometrial Neoplasms" by people in this website by year, and whether "Endometrial Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 0 | 2 |
1995 | 1 | 1 | 2 |
1996 | 2 | 2 | 4 |
1997 | 1 | 0 | 1 |
1998 | 1 | 0 | 1 |
1999 | 2 | 0 | 2 |
2001 | 4 | 0 | 4 |
2002 | 3 | 0 | 3 |
2003 | 2 | 0 | 2 |
2004 | 2 | 0 | 2 |
2005 | 2 | 0 | 2 |
2006 | 2 | 0 | 2 |
2007 | 4 | 0 | 4 |
2008 | 4 | 0 | 4 |
2009 | 6 | 0 | 6 |
2010 | 3 | 0 | 3 |
2011 | 4 | 0 | 4 |
2012 | 8 | 0 | 8 |
2013 | 5 | 0 | 5 |
2014 | 4 | 0 | 4 |
2015 | 10 | 0 | 10 |
2016 | 2 | 0 | 2 |
2017 | 11 | 0 | 11 |
2018 | 5 | 0 | 5 |
2019 | 3 | 0 | 3 |
2020 | 5 | 0 | 5 |
2021 | 1 | 0 | 1 |
2022 | 7 | 0 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Endometrial Neoplasms" by people in Profiles.
-
Identification of Candidate Biomarker and Drug Targets for Improving Endometrial Cancer Racial Disparities. Int J Mol Sci. 2022 Jul 14; 23(14).
-
Hysterectomy with a general gynecologist vs gynecologic-oncologist in the setting of endometrial intraepithelial neoplasia: a cost-effectiveness analysis. Am J Obstet Gynecol. 2022 10; 227(4):609.e1-609.e8.
-
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. Gynecol Oncol. 2022 07; 166(1):44-49.
-
Sera Protein Signatures of Endometrial Cancer Lymph Node Metastases. Int J Mol Sci. 2022 Mar 18; 23(6).
-
Adiposity and breast, endometrial, and colorectal cancer risk in postmenopausal women: Quantification of the mediating effects of leptin, C-reactive protein, fasting insulin, and estradiol. Cancer Med. 2022 02; 11(4):1145-1159.
-
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. Gynecol Oncol. 2022 03; 164(3):481-491.
-
Endometrial Cancer Characteristics and Risk of Recurrence. Am J Clin Pathol. 2022 Jan 06; 157(1):90-97.
-
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021 05 15; 27(10):2734-2741.
-
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol. 2020 11 20; 38(33):3841-3850.
-
Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion. Int J Gynecol Cancer. 2020 11; 30(11):1738-1747.